Medical News

RSS

First Edition: April 4, 2011

Today's health policy news coverage includes reports about Republican lawmakers' plans to make dramatic changes to Medicare and Medicaid as they seek to cut $4 trillion from the budget over the next 10 years.

4 Apr 2011

Aspirin usage associated with decrease in pancreatic cancer risk

The use of aspirin at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

GeneLink net sales decrease 8.4% to $7,839,972 for 2010

GeneLink, Inc., a leading consumer genomics biotech company, today reported financial results for the fiscal year ended December 31, 2010.

4 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

DJO Global intends to offer $300 million in senior notes due 2018

DJO Global, Inc. today announced that its indirect wholly owned subsidiaries, DJO Finance LLC and DJO Finance Corporation, a wholly owned subsidiary of DJOFL, intend to offer, in a private offering subject to market and other conditions, $300 million aggregate principal amount of senior unsecured notes due 2018.

4 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

AngioDynamics introduces DuraMax chronic dialysis catheter in the U.S.

AngioDynamics announced today the U.S. launch and initial shipments of the next generation DuraMax stepped-tip chronic dialysis catheter and the DuraMaxVP kit.

4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Esaote acquires 3mensio

Esaote International NV and 3mensio Medical Imaging BV have entered into an agreement pursuant to which Esaote acquires 3mensio in order to expand its leading role in healthcare information technology.

4 Apr 2011

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

Miltenyi Biotec launches MACSQuant VYB benchtop flow cytometer

Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters.

4 Apr 2011

New anti-angiogenic therapy can lead to tumour growth inhibition

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a natural protein first discovered at QUB. Anti-angiogenics prevent the growth of new blood vessels in tumours and starve them of nutrients, leading to inhibition of tumour growth.

4 Apr 2011

OncoSec acquires certain assets of Inovio

OncoSec Medical Incorporated, a developer of innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today that on March 24, 2011 it completed its acquisition of certain assets of Inovio Pharmaceuticals, Inc. and entered into a license agreement with Inovio, pursuant to the terms of an asset purchase agreement with Inovio entered into on March 14, 2011.

4 Apr 2011

BUSPH, The Partnership at Drugfree.org collaborate to increase 'Join Together' resource utilization

The Partnership at Drugfree.org, in cooperation with the Boston University School of Public Health, announced today that Join Together has become part of the 25-year-old nonprofit organization based in New York City.

4 Apr 2011

Precise Match-on-Card technology achieves quick result in MINEX II evaluation

As the results from the MINEX II test is released, Precise Biometrics emerges with the fastest standardized Match-on-Card technology showing outstanding performance.

4 Apr 2011

Abiomed presents Impella PROTECT II study final results in PCI at ACC and i2 Summit

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the final results from the PROTECT II study, presented by William O'Neill, M.D., Dean of University of Miami and Principal Investigator of PROTECT II, at the American College of Cardiology's 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.

4 Apr 2011

GLT changes its brand name to Nordson EFD Deutschland

GLT GmbH, a leading distributor of Nordson EFD precision dispensing systems, has been rebranded as Nordson EFD Deutschland.

4 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

AtlantiCare to use MEDai's Risk Navigator solutions for patient management

AtlantiCare, the largest health system in southeastern New Jersey, will allow its healthcare providers to better manage patient populations and track clinical and financial objectives with quality-focused tools from Elsevier/MEDai, a leading provider of predictive analytic solutions.

4 Apr 2011